Tirzepatide is best known as a weight-loss and blood-sugar drug. Whether it also protects the heart has been a separate question. In the big cardiovascular outcomes trial, SURPASS-CVOT, tirzepatide was compared with another drug, dulaglutide, rather than with placebo, which makes its absolute benefit hard to read. This analysis tries to estimate it indirectly. The result looks favorable, but the method, and who wrote the paper, both deserve a careful look.
How the estimate was built
The researchers did not run a new trial. They took the hazard ratio (HR) for tirzepatide versus dulaglutide in SURPASS-CVOT and multiplied it by the HR for dulaglutide versus placebo in an earlier trial, REWIND. The result is an imputed tirzepatide-versus-placebo comparison.
The analysis used 2,055 of the 9,901 REWIND participants, those who would have been eligible for SURPASS-CVOT, together with all 13,165 SURPASS-CVOT participants. Propensity score estimation was used to adjust for differences between the two populations. All participants had type 2 diabetes and established atherosclerotic cardiovascular disease. The comparison was prespecified but described as exploratory.
What it estimated
Tirzepatide versus imputed placebo was associated with:
- Lower MACE-3 (the primary composite of major cardiovascular events): HR 0.72 (95% CI 0.55, 0.94)
- Lower death from cardiovascular causes or heart failure events: HR 0.70 (95% CI 0.51, 0.96)
- Lower all-cause death: HR 0.61 (95% CI 0.45, 0.82)
Sensitivity analyses, including unadjusted analyses, the entire REWIND population, and data from a recent GLP-1 receptor agonist meta-analysis that included REWIND, were generally consistent.
Why "estimate" is the operative word
- It is indirect. Nobody compared tirzepatide with placebo in one trial. The estimate rests on the assumption that dulaglutide's effect in REWIND carries over to the SURPASS-CVOT population, and that statistical adjustment closes the gaps between two different trials.
- A selected subset. Only 2,055 of 9,901 REWIND participants (about one in five) entered the main analysis.
- Some intervals sit close to 1. The MACE-3 interval runs up to 0.94 and the cardiovascular death or heart failure interval up to 0.96, so the margins are not large.
- Exploratory. This kind of analysis can suggest an effect size; it cannot replace a placebo-controlled trial.
- Specific population. The findings apply to people with type 2 diabetes and established atherosclerotic disease, not to people using tirzepatide for weight loss without those conditions.
Who wrote it
Seven of the 21 listed authors are current employees and shareholders of Eli Lilly and Company, which makes tirzepatide. Many other authors disclose consulting fees, speaker honoraria or research funding from Lilly and other drug makers. Conflicts of interest do not make results wrong, but they are a reason to want independent confirmation.
Our reading: this analysis is consistent with tirzepatide reducing cardiovascular events in people with diabetes and heart disease, and the direction is encouraging. It is a manufacturer-linked, indirect estimate, and it should be read as a reasonable projection, not as proof. Whether tirzepatide is right for a specific person is a decision for them and their physician.
This article is for general education and is not medical advice.